Repligen Completes Expansion of Manufacturing Facility
Repligen completes expansion of its manufacturing facilities at its Massachusetts headquarters.
Repligen has completed a 9,000-ft2 expansion of its manufacturing facilities at its Waltham, Massachusetts’s headquarters. The production suite more than doubles capacity for Repligen’s OPUS line of prepacked chromatography columns, with cleanrooms built to ISO 7 specifications providing an appropriately controlled environment for GMP production.
The facility expansion also triples warehouse space and includes purification and fermentation laboratories for optimization of existing manufacturing processes, new product development, and applications support. An additional 17,000 ft2 of space is reserved for future expansion of the same facility.
Source: Repligen
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
